ClinicalTrials.gg
RecruitingNCT02705846GENPROSUpdated Oct 29, 2026

Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations

An observational study in Prostate Cancer, sponsored by Institute of Cancer Research, United Kingdom. Recruiting at 1 site in United Kingdom. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Institute of Cancer Research, United Kingdom · Observational

How we know

From the registry’s dates

  • Started Sep 2014; still recruiting 12 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
4,260
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom — 13 open to participants now, 18 under way, 1 of them phase 3. Prostatic Neoplasms · Institute of Cancer Research, United Kingdom.

Planned enrollment
4th of 16
4,260 · median 1,000
Started
2014
the only one that year
Observational
16 of 26
8 open now
Primary completion
2030-12
later than 16 of 17 live
Registered
8th of 26
by date

Among the 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom, this one is the 4th largest by planned enrollment of the 16 observational ones that give a count, is the only one that started in 2014, is one of 16 observational ones, reaches primary completion later than 16 of the 17 other live ones, and was the 8th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

13 of the 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom are open now, in 5 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 13 open studies →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Prostatic Neoplasms by Institute of Cancer Research, United Kingdom, or all of them as a file.
02

Study summary

GENPROS aims to analyse the outcomes of patients with rare gene mutations in the cancer predisposition genes, BRCA1, BRCA2, HOXB13, and Lynch Syndrome, after a diagnosis of and treatment for prostate cancer (PCa). The study includes a cohort of gene mutation carriers with PCa matched with a control group of men with PCa who are known not to carry a mutation in the same gene. Clinical data regarding treatment and patient outcome will be collected retrospectively and prospectively. Archived tumour samples will also be collected for tumour profiling. A blood or saliva sample will be taken, if the participant consents to this part of the study, for genetic profiling to investigate any association of other inherited factors with PCa outcomes. Information obtained from this study will be of critical importance to support clinical trials investigating the most appropriate management of PCa in this group of patients at increased risk of prostate cancer.

Read the detailed description

Over 900,000 new cases of prostate cancer (PCa) are diagnosed worldwide every year. PCa is rarely diagnosed in men younger than 50 years, but its incidence rises rapidly thereafter. Excluding advanced age, the strongest risk factor for the disease is a family history of PCa suggesting the importance of genetic factors in disease development. Genome wide association studies (GWAS) have identified over 70 susceptibility loci associated with modest relative risks of PCa, which taken together, explain about 30% of the familial PCa risk. Rarer genetic variants conferring higher PCa risks have also been identified, such as BRCA1, BRCA2, HOXB13, and the Lynch Syndrome genes. Although the majority of PCa patients may only need active surveillance or are cured with radical primary treatment, others will eventually succumb to advanced disease. In fact, PCa accounts for the second commonest cause of male cancer-related deaths in the United States and the sixth worldwide, with more than 250,000 deaths a year. Thus, it is essential to identify upfront those patients with a lethal form of PCa and several studies have suggested that BRCA1 and BRCA2 mutation carriers may constitute one such population.

BRCA mutations Germline BRCA2 mutations are the genetic events that confer the highest risk of PCa known to date (8.6-fold in men ≤65 years) whilst the effect of BRCA1 is more modest (3.5-fold). Germline BRCA2 and BRCA1 mutations are present in 1.2% and 0.44% of sporadic PCa cases, respectively. Deleterious germline mutations in both the BRCA1 and BRCA2 genes have been associated with more aggressive disease and poor clinical outcomes.

We have recently reported the analysis of 2019 PCa patients, 18 and 61 of them harbouring BRCA1 and BRCA2 germline mutations, respectively. This is the largest study to date investigating the clinical characteristics and outcome of PCa patients with and without BRCA mutations. Our results reveal that a wide spectrum of pathogenic mutations in the BRCA1 and BRCA2 genes confers a more aggressive PCa phenotype and these tumours are more frequently associated with lymph node involvement and distant metastasis at diagnosis than PCa in non-carriers. BRCA1 and BRCA2 carriers had a higher incidence of poorly differentiated tumours, presented with larger tumours and a higher incidence of node involvement and distant metastasis. We have also demonstrated that BRCA2 germline mutations in PCa, are a prognostic factor for poor overall survival, cause specific survival and metastasis free survival, independently of other classical prognostic factors, including stage, Gleason score, and PSA. In our series we observed that although BRCA1 carriers presented with similar baseline risk characteristics as BRCA2 carriers, their survival parameters were more similar to those in non-carriers. BRCA2 but not BRCA1 status, was confirmed as an independent prognostic factor for PCa outcome. Nevertheless, our study and others included a small number of BRCA1 carriers due to the relatively low incidence of PCa in carriers of these mutations and the conclusions regarding this group of patients should be taken cautiously.

The studies mentioned above suggest that PCa associated with germline BRCA mutations may respond differently to the conventional treatments currently available for PCa. In the general population, a multidisciplinary approach is used and treatment options include active surveillance, surgery, radiotherapy (external beam or brachytherapy), androgen deprivation therapy and chemotherapy. No studies to date have investigated whether there is an optimal treatment strategy specifically for BRCA mutation carriers. Therefore, a large study to analyze the outcomes of BRCA carriers after treatment with radical surgery, radiotherapy and chemotherapy is urgently needed as this would enable tailored management for these patients. The implementation of early diagnosis in these patients may also be crucial and currently the IMPACT study is evaluating the utility of PSA-based PCa screening in asymptomatic BRCA carriers.

Lynch Syndrome Another group in which a higher PCa risk has been reported is Lynch syndrome patients. Lynch syndrome is a multi-cancer syndrome caused by germline mutations in the MMR genes; MLH1, MSH2 or MSH6. Colorectal cancers are the predominant cancer phenotype and patients with this syndrome have a 70% probability of developing the disease by the age of 70. In addition, there is an increased risk of extracolonic tumours, including endometrium, stomach, small bowel, ovary, ureter, renal pelvis, biliary tract brain and pancreas. PCa has been reported in these families, but it is not until recently that it has been shown to be a feature of the Lynch syndrome. At the moment, little is known about the association between germline mutations in these genes and the PCa phenotype and outcome. Prostate cancer has been described as a component tumour of Lynch syndrome. The estimated cumulative lifetime risk is two-fold higher than the general population. The cumulative risk of prostate cancer at the age of 60 was 6.3% and at the age of 80 was 30%.

HOXB13 Recently, a rare, recurrent mutation (G84E) in HOXB13, in the 17q21-12 region was reported to be associated with prostate cancer risk. The homeobox transcription factor gene is important in prostate development. The HOXB13 G84E mutation is found in up to 5% of PCa families, mainly in Northern Europe. Another group undertook a systematic literature review of the Germline Homeobox B13 G84E mutation studies in European Descendants. A meta-analysis of 24213 cases of PCa and 73631 controls was conducted and confirmed that HOXB13 G84E mutation is associated with an increased prostate cancer risk with an Odds ratio of 4.07 (95%CI:3.05-5.45). A subgroup analysis based on ethnic origin revealed that the Odds ratio was highest for the Western Europeans (OR=8.66) and lowest for Northern Europeans (OR=3.63). The G84E mutation was associated with early onset PCa with an Odds Ratio of 10.11 for early onset PCa and 3.63 for late onset PCa. When assessing the aggressiveness of the disease, the G84E mutation appeared not to predict a more aggressive presentation. While further studies are needed to define the clinical utility of these observations, it has been suggested that this variant may also be associated with features of more undifferentiated tumours and therefore may be associated with more aggressive disease.

1. Rationale GENPROS aims to observe the outcomes in patients with rare germline genetic variants including BRCA1, BRCA2, HOXB13, MMR gene mutation carriers following prostate cancer (PCa) diagnosis and treatment.

The primary endpoint is the relative Cause Specific Survival (CSS) for men with PCa and a germline mutation in a prostate cancer predisposition gene. This will be of critical importance to support clinical trials investigating the most appropriate management of PCa in this group of high risk patients.

The study includes a cohort of rare gene mutation carriers with PCa and a control group formed of PCa patients known not to carry mutations in the same genes for comparison. In the first instance, carriers of mutations in the BRCA1 and BRCA2 genes will be recruited and as other gene variants are tested in the clinical and research settings, we will expand the protocol to examine these associations also.

Clinical data regarding diagnosis, treatment, recurrence and outcomes of PCa will be collected retrospectively and prospectively through contact with the participant's treating team. All men from this study will be followed-up for at least five years after enrolment in the study.

A sample of the participant's PCa will also be requested for molecular profiling, as well as their family history of cancer. We will also collect a sample of DNA for investigation of common allele profiles and specific common alleles and their association with prognosis and outcomes.

The study will be undertaken at a number of international sites, subject to IRB approval.

03

Conditions studied

  • Prostate Cancer

Keywords

  • BRCA1
  • BRCA2
  • Lynch Syndrome
  • Genetic predisposition to Prostate cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study includes a cohort of rare gene mutation carriers with PCa and a control group formed of PCa patients known not to carry mutations in the same genes for comparison.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men diagnosed with PCa are eligible if:
  • known carriers of germline mutations associated with PCa risk OR
  • known non-carriers of mutations in the genes above

Exclusion criteria

Exclusion Criteria:

  • patients under 18 years of age
  • patients who are unable to give
  • patients who cannot be traced (\<6 months follow-up) or whose clinical data are not available
  • patients whose genetic status is unknown
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
4,260 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Mutation carriers with Prostate cancer

    Men with prostate cancer and a known pathogenic germline mutation in: 1. the BRCA1 or BRCA2 gene 2. the HOXB13 gene 3. The MSH2 gene 4. All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM) 5. The ATM gene 6. Other PCa predisposition genes

    Other: Observation of treatment outcomes via Questionnaire

  • Mutation non carriers

    Men with prostate cancer who have tested negative for a mutation in one of the following genes: 1. the BRCA1 or BRCA2 gene 2. the HOXB13 gene 3. The MSH2 gene 4. All other Lynch Syndrome genes (MLH1, MSH6, PMS2, EPCAM) 5. The ATM gene 6. Other PCa predisposition genes

    Other: Observation of treatment outcomes via Questionnaire

Interventions

  • OtherObservation of treatment outcomes via Questionnaire

    Collection of treatment data from participants

06

What researchers measure

Primary outcomes

  1. Cause Specific Survival (CSS) will be measured in men with prostate cancer who carry a rare germline mutation and compared to CSS in non-carriers

    Survival will be calculated from the date of PCa diagnosis until date of death from any cause or censored at the last follow-up

    Time frame: 60 months

Secondary outcomes

  1. Biochemical progression free survival (bPFS) will be measured and compared between mutation carriers and non-carriers.

    Survival will be calculated from the date of PCa diagnosis until date of death from any cause or censored at the last follow-up

    Time frame: 60 months

  2. Metastasis free survival (MFS) after radical treatment will be measured and compared between mutation carriers and non-carriers.

    Survival will be calculated from the date of PCa diagnosis until date of death from any cause or censored at the last follow-up

    Time frame: 60 months

  3. Overall survival will be measured and compared between mutation carriers and non-carriers.

    Survival will be calculated from the date of PCa diagnosis until date of death from any cause or censored at the last follow-up

    Time frame: 60 months

07

Study locations

1 of 1 sites recruiting
  • Institute of Cancer Research and Royal Marsden Hospital
    Sutton, Surrey SM2 5PT, United Kingdom
    Recruiting
    • Rosalind A Eeles, FRCP FRFR · Contactrosalind.eeles@icr.ac.uk · 02086613642
    • Rosalind A Eeles, FRCP FRCR · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Anonymised data can be applied for via the Steering Commitee

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2014 (actual). Primary completion is estimated for Dec 2030, 195 months after the start.

Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 195 months is above that.

Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2016
First posted
Mar 11, 2016
StartActual
Sep 2014
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2035
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and date precision
1 update, last Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Minor edits only
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02705846
Responsible party
Sponsor
First posted
Mar 11, 2016
Start date
Sep 2014
Primary completion
Dec 2030 (estimated)
Completion
Dec 2035 (estimated)
Last update
Oct 29, 2026

Study contacts

Elizabeth C Page, MSc
Contact
elizabeth.page@icr.ac.uk
44 208 722 4483
Elizabeth Bancroft, PhD
Contact
elizabeth.bancroft@rmh.nhs.uk
44 208 722 4483
Rosalind A Eeles, PhD
principal investigator · Institute of Cancer Research, United Kingdom

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion